ArticleNature communications2024
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19.
Erratum issuedAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Substrate-Selective Inhibition of the SARS-CoV-2 Papain-Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.Journal of virology · 2026Article
- Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches.Molecules (Basel, Switzerland) · 2026Review
- Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research.Microbial biotechnology · 2026Review
- Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design toJournal of medicinal chemistry · 2026Article
- Potential Activity of 6-Pentyl-α-pyrone as an Antiviral for Bovine Coronavirus.Pathogens (Basel, Switzerland) · 2026Article
- Metabolites from South African Medicinal Plants as Dual-Function Inhibitors of the SARS-CoV-2 Papain-like Protease (PLLife (Basel, Switzerland) · 2026Article
- Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease.Molecules (Basel, Switzerland) · 2026Review
- YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice.Nature communications · 2026Article
- Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model.Acta pharmaceutica Sinica. B · 2026Article
- Chasing allosteric inhibition of the SARS-CoV-2 PLpro via molecular dynamics simulations with flooding fragments (MDFFr).Journal of computer-aided molecular design · 2025Article
- SARS-CoV‑2 Papain-Like Protease Inhibitors Based on Naphthalen-1-ylethanamine and Halogenated Benzene Moieties.ACS omega · 2025Article
- Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV‑2 Papain-like Protease (PLACS omega · 2025Article
- Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity.PLoS pathogens · 2025Article
- Structural Features and In Vitro Antiviral Activities of Fungal Metabolites Sphaeropsidins A and B Against Bovine Coronavirus.International journal of molecular sciences · 2025Article
- PLpro Inhibitors as a Potential Treatment for COVID-19.Biomedicines · 2025Article
- Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like protease.Nature communications · 2025Article
- A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.Nature communications · 2025Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
24 authors.
Yongzhi Lu *Guangzhou National Laboratory, Guangzhou, 510005, China.ORCID 0000-0002-9985-8546
Qi Yang *Guangzhou National Laboratory, Guangzhou, 510005, China.ORCID 0009-0009-1648-4189
Ting Ran *Guangzhou National Laboratory, Guangzhou, 510005, China.ORCID 0000-0002-1387-4634
Guihua ZhangGuangzhou National Laboratory, Guangzhou, 510005, China.
Wenqi LiGuangzhou National Laboratory, Guangzhou, 510005, China.
Peiqi ZhouGuangzhou National Laboratory, Guangzhou, 510005, China.
Jielin TangGuangzhou National Laboratory, Guangzhou, 510005, China.
Minxian DaiGuangzhou National Laboratory, Guangzhou, 510005, China.
Jinpeng ZhongGuangzhou National Laboratory, Guangzhou, 510005, China.
Hua ChenGuangzhou National Laboratory, Guangzhou, 510005, China.
Pan HeGuangzhou National Laboratory, Guangzhou, 510005, China.
Anqi ZhouSchool of Basic Medical Sciences, Guangzhou Laboratory, Guangzhou Medical University, Guangzhou, 511436, China.
Bao XueGuangzhou National Laboratory, Guangzhou, 510005, China.
Jiayi ChenGuangzhou National Laboratory, Guangzhou, 510005, China.
Jiyun ZhangGuangzhou National Laboratory, Guangzhou, 510005, China.
Sidi YangGuangzhou National Laboratory, Guangzhou, 510005, China.
Kunzhong WuGuangzhou National Laboratory, Guangzhou, 510005, China.
Xinyu WuGuangzhou National Laboratory, Guangzhou, 510005, China.
Miru TangGuangzhou National Laboratory, Guangzhou, 510005, China.
Wei K ZhangGuangzhou National Laboratory, Guangzhou, 510005, China.ORCID 0000-0003-4960-6137
Deyin GuoGuangzhou National Laboratory, Guangzhou, 510005, China.ORCID 0000-0002-8297-0814
Xinwen ChenGuangzhou National Laboratory, Guangzhou, 510005, China. chen_xinwen@gzlab.ac.cn.ORCID 0000-0002-4052-8155
Hongming ChenGuangzhou National Laboratory, Guangzhou, 510005, China. chen_hongming@gzlab.ac.cn.ORCID 0000-0002-8065-8333
Jinsai ShangGuangzhou National Laboratory, Guangzhou, 510005, China. shang_jinsai@gzlab.ac.cn.ORCID 0000-0001-8164-1544
Funding
National Natural Science Foundation of China (National Science Foundation of China) 821704730Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2021CX020227
Abstract
The RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CL
Indexed as
Antiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2Administration, OralAnimalsChlorocebus aethiopsCoronavirus 3C ProteasesCoronavirus Papain-Like ProteasesCOVID-19Drug DesignDrug DiscoveryFemaleHumansMiceProtease InhibitorsVero CellsAntiviral AgentsCoronavirus 3C ProteasesCoronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2Protease Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.